Universität zu Köln

Shah-Hosseini, Kija ORCID: 0000-0001-9616-6942, Krudewig, Eva-Maria, Hadler, Meike, Karagiannis, Efstrathios and Moesges, Ralph (2017). Management of Grass Pollen Allergy with 5-Grass Pollen Tablet: Results of a 2-Year Real-Life Study. Adv. Ther., 34 (6). S. 1382 - 1398. NEW YORK: SPRINGER. ISSN 1865-8652

Full text not available from this repository.

Abstract

Introduction: Allergen immunotherapy is the only treatment option for allergic rhinitis with disease-altering potential. It was the objective of this study to assess the effectiveness and tolerability of a 5-grass pollen tablet in a large population of non-selected grass pollen allergic patients, i. e. patients with different clinical profiles in daily clinical practice. Methods: In a 2-year, prospective, open-label, multicenter, non-controlled, observational study patients were included from 327 centers across Germany. Rhinoconjunctivitis symptoms, symptomatic medication intake and adverse events were recorded. Results: A total of 1482 patients aged 4-75 years were included. During the 2-year period of 5-grass pollen tablet therapy, mean rhinoconjunctivitis score decreased significantly in the overall study population by 65.5% (P < 0.001). The percentage of patients taking symptomatic medication decreased from 83.8% to 42.7%. Mean 2-year improvements in rhinoconjunctivitis scores and decreases in the percentage of patients taking symptomatic medication were broadly similar in adults, adolescents and children, in patients with polyallergy versus monoallergy, and in patients with/without asthma. Among polyallergic patients, concomitant application of another specific immunotherapy did not impair treatment outcomes. Adverse drug reactions, predominantly affecting the local application area, occurred in 15.4% of the overall patient population (n = 229). No cases of anaphylaxis or epinephrine use were documented. Conclusion: This study indicates that sublingual immunotherapy with the 5-grass pollen tablet is well tolerated and provides sustained effectiveness over 2 years in patients with different clinical profiles, producing a significant decrease in allergic symptoms and a reduction in the use of symptomatic medication.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Shah-Hosseini, Kija UNSPECIFIED orcid.org/0000-0001-9616-6942 UNSPECIFIED Krudewig, Eva-Maria UNSPECIFIED UNSPECIFIED UNSPECIFIED Hadler, Meike UNSPECIFIED UNSPECIFIED UNSPECIFIED Karagiannis, Efstrathios UNSPECIFIED UNSPECIFIED UNSPECIFIED Moesges, Ralph UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-228858
DOI:	10.1007/s12325-017-0535-6
Journal or Publication Title:	Adv. Ther.
Volume:	34
Number:	6
Page Range:	S. 1382 - 1398
Date:	2017
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1865-8652
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language SUBLINGUAL IMMUNOTHERAPY TABLETS; POLYSENSITIZED PATIENTS; EFFICACY; RHINITIS; SAFETY; CHILDREN; ASTHMA; SENSITIZATIONS; STRATEGIES; INHALANT Multiple languages Medicine, Research & Experimental; Pharmacology & Pharmacy Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/22885